CollPlant Bio (CLGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CLGN Stock Forecast

CollPlant Bio stock forecast is as follows: an average price target of $14.00 (represents a 234.13% upside from CLGN’s last price of $4.19) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CLGN Price Target

The average price target for CollPlant Bio (CLGN) is $14.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 234.13% upside from CLGN's last price of $4.19.

CLGN Analyst Ratings

Buy

According to 1 Wall Street analysts, CollPlant Bio's rating consensus is 'Buy'. The analyst rating breakdown for CLGN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CollPlant Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 05, 2024	Jason Kolbert	EF Hutton	$14.00	$4.65	201.08%	234.13%

Row per page

Go to

The latest CollPlant Bio stock forecast, released on Aug 05, 2024 by Jason Kolbert from EF Hutton, set a price target of $14.00, which represents a 201.08% increase from the stock price at the time of the forecast ($4.65), and a 234.13% increase from CLGN last price ($4.19).

CollPlant Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$14.00
Last Closing Price	$4.19	$4.19	$4.19
Upside/Downside	-100.00%	-100.00%	234.13%

In the current month, the average price target of CollPlant Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CollPlant Bio's last price of $4.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 21, 2024	EF Hutton	Underperform	Underperform	Hold
Aug 21, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 05, 2024	EF Hutton	-	Buy	Initialise

Row per page

Go to

CollPlant Bio's last stock rating was published by EF Hutton on Aug 21, 2024. The company gave CLGN a "Underperform" rating, the same as its previous rate.

CollPlant Bio Financial Forecast

CollPlant Bio Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$433.00K	$58.00K	$109.00K	$66.00K	$66.00K	-	$140.00K
Avg Forecast	$4.05M	$3.90M	$3.60M	$3.45M	$2.29M	$2.21M	$2.04M	$1.96M	$4.86M	$4.68M	$4.32M	$4.14M	$2.50M	$2.35M	$6.38M	$1.77M	$432.00K	$416.00K	$395.50K	$642.00K	$8.56M	$3.50M	$3.59M	$238.33K	$100.00K	$3.10M	$2.86M	$2.74M	$338.00K	$246.00K
High Forecast	$4.05M	$3.90M	$3.60M	$3.45M	$2.29M	$2.21M	$2.04M	$1.96M	$4.86M	$4.68M	$4.32M	$4.14M	$2.50M	$2.35M	$6.38M	$1.77M	$432.00K	$416.00K	$395.75K	$642.00K	$8.56M	$3.50M	$3.59M	$238.33K	$100.00K	$3.10M	$2.86M	$2.74M	$338.00K	$246.00K
Low Forecast	$4.05M	$3.90M	$3.60M	$3.45M	$2.29M	$2.21M	$2.04M	$1.96M	$4.86M	$4.68M	$4.32M	$4.14M	$2.50M	$2.35M	$6.38M	$1.77M	$432.00K	$416.00K	$395.25K	$642.00K	$8.56M	$3.50M	$3.59M	$238.33K	$100.00K	$3.10M	$2.86M	$2.74M	$338.00K	$246.00K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.82%	0.58%	0.04%	0.02%	0.02%	-	0.57%

CollPlant Bio's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.59M, with a low forecast of $3.59M, and a high forecast of $3.59M. CLGN's average Quarter revenue forecast represents a 729.48% increase compared to the company's last Quarter revenue of $433.00K (Mar 23).

CollPlant Bio EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.24M	$-4.38M	$-4.19M	$-3.92M	$-3.53M	-	$-2.87M
Avg Forecast	$-2.70M	$-2.60M	$-2.40M	$-2.30M	$-1.53M	$-1.47M	$-1.36M	$-1.30M	$-3.24M	$-3.12M	$-2.88M	$-2.76M	$-1.67M	$-1.56M	$-4.26M	$-1.18M	$-288.24K	$-277.56K	$-263.89K	$-428.36K	$-5.71M	$-2.34M	$-2.40M	$-159.02K	$-66.72K	$-2.06M	$-1.90M	$-1.82M	$-225.04K	$-2.77M
High Forecast	$-2.70M	$-2.60M	$-2.40M	$-2.30M	$-1.53M	$-1.47M	$-1.36M	$-1.30M	$-3.24M	$-3.12M	$-2.88M	$-2.76M	$-1.67M	$-1.56M	$-4.26M	$-1.18M	$-288.24K	$-277.56K	$-263.72K	$-428.36K	$-5.71M	$-2.34M	$-2.40M	$-159.02K	$-66.72K	$-2.06M	$-1.90M	$-1.82M	$-225.04K	$-2.22M
Low Forecast	$-2.70M	$-2.60M	$-2.40M	$-2.30M	$-1.53M	$-1.47M	$-1.36M	$-1.30M	$-3.24M	$-3.12M	$-2.88M	$-2.76M	$-1.67M	$-1.56M	$-4.26M	$-1.18M	$-288.24K	$-277.56K	$-264.05K	$-428.36K	$-5.71M	$-2.34M	$-2.40M	$-159.02K	$-66.72K	$-2.06M	$-1.90M	$-1.82M	$-225.04K	$-3.32M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.37%	65.68%	2.03%	2.06%	1.94%	-	1.04%

undefined analysts predict CLGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CollPlant Bio's previous annual EBITDA (undefined) of $NaN.

CollPlant Bio Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.91M	$-4.13M	$-4.29M	$-4.38M	$-3.95M	-	$-3.08M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-3.55M	$-3.55M	$3.32M	$-4.24M	$-3.15M	$-3.26M	$-3.09M	$-4.01M	$2.75M	$-1.49M	$-954.54K	$-3.32M	$-3.61M	$-3.55M	$-916.36K	$-1.60M	$-3.32M	$-2.97M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-3.55M	$-3.55M	$3.32M	$-4.24M	$-3.15M	$-3.26M	$-3.09M	$-4.01M	$2.75M	$-1.49M	$-954.54K	$-3.32M	$-3.61M	$-3.55M	$-916.36K	$-1.60M	$-3.32M	$-2.37M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-3.55M	$-3.55M	$3.32M	$-4.24M	$-3.15M	$-3.26M	$-3.09M	$-4.01M	$2.75M	$-1.49M	$-954.54K	$-3.32M	$-3.61M	$-3.55M	$-916.36K	$-1.60M	$-3.32M	$-3.56M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.18%	1.14%	1.21%	4.79%	2.46%	-	1.04%

CollPlant Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

CollPlant Bio SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.52M	$2.04M	$1.54M	$1.61M	$1.56M	-	$1.18M
Avg Forecast	$20.89M	$20.12M	$18.57M	$17.80M	$11.84M	$11.40M	$10.52M	$10.09M	$25.07M	$24.14M	$22.29M	$21.36M	$12.91M	$12.10M	$32.92M	$9.14M	$2.23M	$2.15M	$2.04M	$3.31M	$44.18M	$18.07M	$18.53M	$1.23M	$515.92K	$15.91M	$14.68M	$14.07M	$1.74M	$1.26M
High Forecast	$20.89M	$20.12M	$18.57M	$17.80M	$11.84M	$11.40M	$10.52M	$10.09M	$25.07M	$24.14M	$22.29M	$21.36M	$12.91M	$12.10M	$32.92M	$9.14M	$2.23M	$2.15M	$2.04M	$3.31M	$44.18M	$18.07M	$18.53M	$1.23M	$515.92K	$15.91M	$14.68M	$14.07M	$1.74M	$1.26M
Low Forecast	$20.89M	$20.12M	$18.57M	$17.80M	$11.84M	$11.40M	$10.52M	$10.09M	$25.07M	$24.14M	$22.29M	$21.36M	$12.91M	$12.10M	$32.92M	$9.14M	$2.23M	$2.15M	$2.04M	$3.31M	$44.18M	$18.07M	$18.53M	$1.23M	$515.92K	$15.91M	$14.68M	$14.07M	$1.74M	$1.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.24%	3.94%	0.10%	0.11%	0.11%	-	0.94%

CollPlant Bio's average Quarter SG&A projection for Jun 23 is $18.53M, based on 1 Wall Street analysts, with a range of $18.53M to $18.53M. The forecast indicates a 1115.08% rise compared to CLGN last annual SG&A of $1.52M (Mar 23).

CollPlant Bio EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.35	$-0.37	$-0.39	$-0.40	$-0.37	-	$-0.29
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-0.31	$-0.31	$0.29	$-0.37	$-0.28	$-0.28	$-0.27	$-0.35	$0.24	$-0.13	$-0.08	$-0.29	$-0.32	$-0.31	$-0.08	$-0.14	$-0.29	$-0.28
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-0.31	$-0.31	$0.29	$-0.37	$-0.28	$-0.28	$-0.27	$-0.35	$0.24	$-0.13	$-0.08	$-0.29	$-0.32	$-0.31	$-0.08	$-0.14	$-0.29	$-0.28
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-0.31	$-0.31	$0.29	$-0.37	$-0.28	$-0.28	$-0.27	$-0.35	$0.24	$-0.13	$-0.08	$-0.29	$-0.32	$-0.31	$-0.08	$-0.14	$-0.29	$-0.28
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.21%	1.17%	1.26%	5.00%	2.64%	-	1.04%

According to undefined Wall Street analysts, CollPlant Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLGN previous annual EPS of $NaN (undefined).

CollPlant Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.28	$15.00	1071.88%	Buy
STTK	Shattuck Labs	$1.14	$12.00	952.63%	Hold
PRLD	Prelude Therapeutics	$0.96	$6.25	551.04%	Sell
MOLN	Molecular Partners	$5.46	$29.00	431.14%	Buy
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
CLGN	CollPlant Bio	$4.19	$14.00	234.13%	Buy
CCCC	C4 Therapeutics	$4.15	$13.50	225.30%	Buy
PRTC	PureTech Health	$21.26	$57.00	168.11%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
REPL	Replimune Group	$10.95	$24.20	121.00%	Buy
XCUR	Exicure	$5.82	$12.00	106.19%	-
KROS	Keros Therapeutics	$53.62	$102.60	91.35%	Buy
MRUS	Merus	$43.49	$77.13	77.35%	Buy
NAMS	NewAmsterdam Pharma Company	$23.68	$36.50	54.14%	Buy
CRNX	Crinetics Pharmaceuticals	$55.17	$70.14	27.13%	Buy
VCEL	Vericel	$55.83	$57.33	2.69%	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

CLGN Forecast FAQ

Is CollPlant Bio a good buy?

Yes, according to 1 Wall Street analysts, CollPlant Bio (CLGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CLGN's total ratings.

What is CLGN's price target?

CollPlant Bio (CLGN) average price target is $14 with a range of $14 to $14, implying a 234.13% from its last price of $4.19. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CollPlant Bio stock go up soon?

According to Wall Street analysts' prediction for CLGN stock, the company can go up by 234.13% (from the last price of $4.19 to the average price target of $14), up by 234.13% based on the highest stock price target, and up by 234.13% based on the lowest stock price target.

Can CollPlant Bio stock reach $6?

CLGN's average twelve months analyst stock price target of $14 supports the claim that CollPlant Bio can reach $6 in the near future.

What are CollPlant Bio's analysts' financial forecasts?

CollPlant Bio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $8.5M (high $8.5M, low $8.5M), average EBITDA is $-5.671M (high $-5.671M, low $-5.671M), average net income is $0 (high $0, low $0), average SG&A $43.85M (high $43.85M, low $43.85M), and average EPS is $0 (high $0, low $0). CLGN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $15M (high $15M, low $15M), average EBITDA is $-10.008M (high $-10.008M, low $-10.008M), average net income is $0 (high $0, low $0), average SG&A $77.39M (high $77.39M, low $77.39M), and average EPS is $0 (high $0, low $0).

Did the CLGN's actual financial results beat the analysts' financial forecasts?

Based on CollPlant Bio's last annual report (Dec 2022), the company's revenue was $299K, which missed the average analysts forecast of $8.79M by -96.60%. Apple's EBITDA was $-16.021M, beating the average prediction of $-5.852M by 173.75%. The company's net income was $-16.753M, beating the average estimation of $-9.679M by 73.08%. Apple's SG&A was $6.74M, missing the average forecast of $45.17M by -85.08%. Lastly, the company's EPS was $-1.52, beating the average prediction of $-0.845 by 79.88%. In terms of the last quarterly report (Mar 2023), CollPlant Bio's revenue was $433K, beating the average analysts' forecast of $238.33K by 81.68%. The company's EBITDA was $-3.239M, beating the average prediction of $-159K by 1936.84%. CollPlant Bio's net income was $-3.911M, beating the average estimation of $-3.322M by 17.74%. The company's SG&A was $1.52M, beating the average forecast of $1.23M by 24.02%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.29 by 20.69%